Anna Protopapas

Anna Protopapas serves as the Chairperson of the Board at Nuvalent, Inc. since March 2022 and has been a Board Member at Mersana Therapeutics since March 2015, where Anna also held the role of President and CEO until retirement. Protopapas has extensive board experience, having served on the boards of Dicerna Pharmaceuticals, Inc., Bioverativ, and ARIAD Pharmaceuticals, Inc. Additionally, Protopapas held leadership positions including President at Millennium: The Takeda Oncology Company and Executive Vice President at Takeda Pharmaceuticals, overseeing Global Licensing and Business Development. Protopapas' educational background includes a Master of Science in Engineering in Chemical Engineering from the Massachusetts Institute of Technology, a Bachelor of Science in Engineering in Chemical Engineering from Princeton University, and an MBA from Stanford University Graduate School of Business. Protopapas is a graduate of The English School in Nicosia, Cyprus.